VERICEL CORP

VCEL is the ticker symbol for Vericel Corporation, a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for sports medicine and severe burn care. The stock trades on the Nasdaq Global Market. Investors often track VCEL as a way to gain exposure to regenerative medicine and cellular therapy, an area with distinct regulatory and clinical risks.

Recent performance for VCEL depends on the latest market session, so the most accurate figures appear in the price and performance section of this page. That section typically shows the latest close, daily change, and short-term returns, which can be compared with broader biotech or healthcare benchmarks to gauge relative momentum.

Valuation for VCEL is often assessed using enterprise value relative to revenue, price-to-sales, and price-to-book ratios, because profitability can be uneven for commercial-stage biopharma companies. Investors may also compare VCEL with peers in cell therapy and regenerative medicine. Current valuation multiples are best taken from the live data on this page rather than from any fixed number.

VCEL is listed on Nasdaq and generally has active daily trading, though volume can vary with news, earnings, and broader market conditions. Liquidity metrics such as average daily volume, bid-ask spread, and market capitalization are shown in the trading data on this page. Those live figures are the most reliable way to judge how easily VCEL shares can be bought or sold.

Dividend policy for VCEL is not fixed and should be confirmed from the company's latest disclosures and the dividend section on this page. Many commercial-stage biopharma companies prioritize reinvesting cash into research, clinical programs, and commercial expansion rather than paying regular dividends, but any change to that approach would be reported by the company.

VCEL faces risks tied to clinical and regulatory outcomes, reimbursement and payer decisions, manufacturing and supply chain reliability, competition from other cell therapy and burn care products, and reliance on a limited number of key products. Broader healthcare policy changes, interest rates, and equity market volatility can also affect the share price. Reviewing SEC filings and the risk factors section is important before making any decision.